These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14037707)

  • 1. [Experience with obtaining of a non-reactogenic vaccine against Q fever].
    SHTERNGOL'D EIa
    Zh Mikrobiol Epidemiol Immunobiol; 1961 Sep; 32():12-8. PubMed ID: 14037707
    [No Abstract]   [Full Text] [Related]  

  • 2. [Associated vaccine against typhus and Q-fever and the possibility of decreased reactogenic properties of the vaccine against Q-fever].
    GOLINEVICH EM; GENIG VA
    Vopr Virusol; 1961; 6():728-32. PubMed ID: 13899955
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunological effectiveness of an associated vaccine against Q fever and brucellosis].
    SILICH VA; FUKI AA; STRIKHANOVA EV; KOZYLBASHEVA MA
    Zh Mikrobiol Epidemiol Immunobiol; 1962 Sep; 33():68-71. PubMed ID: 13912835
    [No Abstract]   [Full Text] [Related]  

  • 4. Intradermal sensitivity testing in man with a purified vaccine for Q fever.
    LACKMAN DB; BELL EJ; BELL JF; PICKENS EG
    Am J Public Health Nations Health; 1962 Jan; 52(1):87-93. PubMed ID: 14461400
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effectiveness of combined immunization against enteric infections and Q fever].
    BELIAKOV VD; IL'CHENKO AA
    Zh Mikrobiol Epidemiol Immunobiol; 1958 Nov; 29(11):29-34. PubMed ID: 13626097
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety test for Q fever vaccine.
    BERMAN S; COLE G; LOWENTHAL JP; GOCHENOUR RB
    J Bacteriol; 1960 May; 79(5):747-51. PubMed ID: 13799600
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: Non-reactogenic vaccines against Q-fever.
    Gregory AE; Davies DH
    Front Immunol; 2023; 14():1196522. PubMed ID: 37215096
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on the duration of post-vaccinal immunity in Q fever].
    FEDOROVA NI; TAV'EV BM; RUMIANTSEVA EV
    Zh Mikrobiol Epidemiol Immunobiol; 1960 Sep; 31():30-2. PubMed ID: 13698554
    [No Abstract]   [Full Text] [Related]  

  • 9. Promiscuous
    Scholzen A; Richard G; Moise L; Baeten LA; Reeves PM; Martin WD; Brauns TA; Boyle CM; Raju Paul S; Bucala R; Bowen RA; Garritsen A; De Groot AS; Sluder AE; Poznansky MC
    Front Immunol; 2019; 10():207. PubMed ID: 30828331
    [No Abstract]   [Full Text] [Related]  

  • 10. [RAMS academician I. V. Tarasevich is a leader of development of combined inactivated vaccine against Q-fever].
    Tokarevich NK
    Vestn Ross Akad Med Nauk; 2008; (7):19-24. PubMed ID: 18756779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia.
    Kazár J; Brezina R; Palanová A; Tvrdá B; Schramek S
    Bull World Health Organ; 1982; 60(3):389-94. PubMed ID: 6982774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with simultaneous immunization of the population with live vaccines against brucellosis and Q-fever].
    Kniazeva EN; Genig VA; Beletskaia GA; Voshchakina NV; Egorova LS; Kostiukov VL; Panina NV; Tsel'nikov PS
    Zh Mikrobiol Epidemiol Immunobiol; 1969 Jan; 46(1):112-7. PubMed ID: 5787559
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011.
    Schoffelen T; Wong A; Rümke HC; Netea MG; Timen A; van Deuren M; Vermeer-de Bondt PE
    Vaccine; 2014 Nov; 32(49):6622-30. PubMed ID: 25446824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.
    Shannon JG; Heinzen RA
    Immunol Res; 2009; 43(1-3):138-48. PubMed ID: 18813881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the optimum doses of antigens for active immunization. I. Determination of the optimum doses of crude diphtheria toxoids.
    PAVLOV PV; LEONOVA AG
    Zh Mikrobiol Epidemiol Immunobiol; 1961; 32():1572-8. PubMed ID: 14038234
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of the Q fever vaccine: a meta-analysis.
    Gefenaite G; Munster JM; van Houdt R; Hak E
    Vaccine; 2011 Jan; 29(3):395-8. PubMed ID: 21094268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience in mass vaccination against Q fever. I. Capacity of Q fever vaccine to produce reactivity and immunity].
    ZUBKOVA RI; FEDOROVA NI; KALMYKOV NL
    Zh Mikrobiol Epidemiol Immunobiol; 1956 Jul; 27(7):24-7. PubMed ID: 13353714
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experiences with combined vaccination against brucellosis and Q fever].
    SILIN VA; SHEVTSOVA ZV
    Zh Mikrobiol Epidemiol Immunobiol; 1962 Jul; 33():66-72. PubMed ID: 13912837
    [No Abstract]   [Full Text] [Related]  

  • 19. Q-fever soluble vaccine effects in Coxiella burneti sensitized humans.
    Crăcea E; Dumitrescu-Constantinescu S; Botez D; Ioanid L
    Zentralbl Bakteriol Orig A; 1977 Jul; 238(3):413-8. PubMed ID: 910580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization in man with a soluble Q fever vaccine.
    Crăcea E; Dumitrescu S; Botez D; Toma E; Bandu C; Sabin S; Ioanid L; Chirescu N
    Arch Roum Pathol Exp Microbiol; 1973 Mar; 32(1):45-51. PubMed ID: 4755168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.